|

Ascentage Pharma HQP1351 bioavailable inhibitor Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Ascentage Pharma Group Inc.1

Indications

  • B Cell Precursor Type Acute Leukemia1
  • Myeloid Leukemia1
  • Philadelphia Positive Acute Lymphoblastic Leukemia1
  • Chronic Myeloid Leukemia1
  • Leukemia,Myeloid, Chronic1

Birmingham, Alabama1 trial

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

University of Alabama at Birmingham

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.